Valuation: Mymetics Corporation

Market Cap 439K 386K 366K 330K 623K 42.07M 631K 4.38M 1.69M 21.51M 1.65M 1.61M 68.95M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.51M 60.17M 54.33M 102M 6.92B 104M 720M 277M 3.54B 271M 265M 11.33B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-5.88% 45
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.54%+0.91%+27.37%+80.39% 60.14B
-1.23%-0.42%+6.14%+34.93% 48.15B
-0.05%+0.37%+41.54%+36.65% 44.25B
+0.38%+7.61%+339.53%+641.55% 43.99B
+0.18%+0.26%+7.41%+103.45% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.29%-3.55%-20.74%+352.04% 24.93B
Average +5.12%+1.38%+106,706.17%+140.64% 39.68B
Weighted average by Cap. +0.83%+1.53%+59.20%+147.46%

Financials

2021 2022
Net sales 430K 379K 359K 324K 610K 41.23M 618K 4.29M 1.65M 21.08M 1.61M 1.58M 67.57M 1.03M 905K 858K 774K 1.46M 98.57M 1.48M 10.26M 3.95M 50.39M 3.86M 3.78M 162M
Net income -4.73M -4.17M -3.95M -3.56M -6.71M -454M -6.8M -47.22M -18.17M -232M -17.76M -17.37M -743M -4.8M -4.23M -4.01M -3.62M -6.82M -461M -6.91M -47.97M -18.46M -236M -18.04M -17.65M -755M
Net Debt 67.1M 59.09M 55.98M 50.54M 95.26M 6.43B 96.49M 670M 258M 3.29B 252M 246M 10.54B 71.68M 63.12M 59.81M 53.99M 102M 6.87B 103M 716M 275M 3.51B 269M 263M 11.27B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock